Last year, pharmaceutical giant AbbVie (NYSE: ABBV) lost patent exclusivity for its biggest cash cow, immunology medicine ...

TriSalus Life Sciences, Inc. ( NASDAQ: TLSI) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Jim Young - Senior Vice President, Investor Relations & Treasurer Mary Szela - President & ...

Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

AbbVie (ABBV) shares snapped eight consecutive sessions of losses as the stock closed up XYZ% at $XYZ. The North ...

In fact, migraines and their related symptoms are estimated to be responsible for the loss of more than 113 million work days in the U.S. each year. To battle those disruptions, AbbVie ...

As of Q3 2024, Humira sales were $2.2 billion globally, but AbbVie's total revenue was $14.4 billion. Its immunology portfolio (which includes all three of the medicines) grew by 3.9% year over ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (NYSE:ABBV) with a Outperform ...

Emraclidine was added to AbbVie’s pipeline with this year’s acquisition of Cerevel ... AbbVie expects to return to robust mid-single-digit revenue growth in 2025 with a high single-digit ...

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...